Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

BfArM grants Moberg Derma approval to initiate Limtop clinical phase I trial for actinic keratosis

The German- Federal Institute for Drugs and Medical Devices (BfArM) has granted Moberg Derma approval to initiate a clinical phase I trial for Limtop. Limtop is an innovative formulation of an immunomodulatory compound with potential to treat actinic keratosis, genital warts and basal cell carcinoma.

11 Mar 2012

FDA clears Hospira's Symbiq 3.13 infusion device

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, announced today that the company has received regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Symbiq 3.13 infusion device, the enhanced version of the company's advanced infusion system platform.

9 Mar 2012

Unigene fourth quarter net income increases to $4.4 million

Unigene Laboratories, Inc., today announced financial results for the fourth quarter and full-year ended December 31, 2011.

9 Mar 2012

FDA approves Discovery Labs' SURFAXIN to prevent Respiratory Distress Syndrome

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that the United States Food and Drug Administration (FDA) has approved SURFAXIN (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS.

6 Mar 2012

Access full year 2011 revenues increase 284%

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and cancer supportive care,announced preliminary revenue results for fourth quarter 2011 and full year 2011. Fourth quarter MuGard product sales increased 400% over third quarter product sales.

5 Mar 2012

New method for creating nanofibers could improve drug delivery methods

A new method for creating nanofibers made of proteins, developed by researchers at Polytechnic Institute of New York University (NYU-Poly), promises to greatly improve drug delivery methods for the treatment of cancers, heart disorders and Alzheimer's disease, as well as aid in the regeneration of human tissue, bone and cartilage.

1 Mar 2012

Inhaled interferon-gamma may effectively treat IPF

Inhaled interferon-gamma may be an effective treatment for idiopathic pulmonary fibrosis (IPF), a chronic and progressive form of lung disease caused by excessive formation of fibrotic, or scar tissue, in the lungs, according to an article published in Journal of Aerosol Medicine and Pulmonary Drug Delivery, a peer-reviewed journal from Mary Ann Liebert, Inc.

1 Mar 2012

Vascular Magnetics to advance development of new drug delivery system for PAD

Vascular Magnetics, the first start-up company spun off by The Children's Hospital of Philadelphia, has raised $7 million to advance development of an innovative drug delivery system using magnetically targeted nanoparticles to treat peripheral artery disease.

28 Feb 2012

FDA issues complete response letter for Watson's progesterone vaginal gel 8% NDA

Watson Pharmaceuticals, Inc. and Columbia Laboratories, Inc. today confirmed that, as expected, Watson has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA 22-139) for progesterone vaginal gel 8% for use in the reduction of risk of preterm birth in women with a singleton gestation and a short uterine cervical length in the mid-trimester of pregnancy.

27 Feb 2012

Rhei granted marketing approval for MuGard in China

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, Rhei Pharmaceuticals HK Ltd., received regulatory and marketing approval for MuGard in China from the State Food and Drug Administration, or SFDA, to treat oral mucositis in cancer patients.

24 Feb 2012

Researchers uncover how phytoplankton release powerful toxins into environment

Each year, phytoplankton blooms known as "red tides" kill millions of fish and other marine organisms and blanket vast areas of coastal water around the world. Though the precise causes of red tides remain a mystery, a team of researchers in the United States and Spain has solved one of the main riddles about these ecological disasters by uncovering the specific mechanism that triggers phytoplankton to release their powerful toxins into the environment.

24 Feb 2012

Impax announces FDA acceptance of NDA filing for IPX066

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for IPX066 for the treatment of idiopathic Parkinson's disease (PD) submitted to the Agency on December 21, 2011.

23 Feb 2012

USPTO rejects MonoSol's patent infringement claims against BDSI

The United States Patent & Trademark Office has informed BioDelivery Sciences International, Inc. that it has rejected all claims by MonoSol Rx, LLC (MonoSol) in its US Patent No. 7,425,292 (the '292 Patent) which is currently being asserted against BDSI and its commercial partners for ONSOLIS.

23 Feb 2012

Modified imatinib cancer drug prevents morphine tolerance in rats

By reformulating the common cancer drug imatinib (Gleevec), researchers have eliminated morphine tolerance in rats - an important step toward improving the effectiveness of chronic pain management in patients, according to researchers at The University of Texas MD Anderson Cancer Center.

20 Feb 2012

Remote controlled microchip successfully delivers drug in early clinical trial

Researchers have developed a new microchip implant device that can deliver bone-building drugs to seven osteoporosis patients. The microchips worked inside patients as drug-delivering pacemakers, following a prescription plan sent by radio signal.

18 Feb 2012

Sensors in Design conference to take place on March 28-29

2012 kicks off the inaugural Design West event in San Jose, CA featuring the Sensors in Design summit. The Sensors in Design conference is set to take place on March 28-29, 2012, featuring sessions lead by the top sensor fabricators as well as leading companies utilizing sensor technology in order to enhance functionality and interactivity in their products.

18 Feb 2012

Alexza prices underwritten public offering of 44,000,000 shares of common stock and warrants

Alexza Pharmaceuticals, Inc., or the Company, today announced that it has priced its previously announced underwritten public offering of 44,000,000 shares of common stock and warrants to purchase 44,000,000 shares of common stock.

17 Feb 2012

Aeroneb drug delivery products receive marketing authorisation in China

Aerogen,the innovative medical device and drug delivery company, has announced receipt of authorisation to market its Aeroneb Pro and Aeroneb Go products in China.

17 Feb 2012

Innocoll completes XaraColl End-of-Phase 2 meeting with FDA

Innocoll, Inc. announced that it has held an End-of-Phase 2 meeting with the FDA to present the results of the Phase 2 clinical studies completed for XaraColl and to discuss the proposed safety and efficacy studies to be conducted in Phase 3. XaraColl is being developed for postoperative analgesia and Innocoll plans to undertake its Phase 3 program in patients undergoing hernia repair.

17 Feb 2012

Greatbatch acquires NeuroNexus

Greatbatch, Inc., today announced the acquisition of NeuroNexus Technologies for approximately $12 million in cash, including the assumption of debt and future considerations.

17 Feb 2012